Abstract
Background Great reductions of respiratory syncytial virus (RSV) in children were observed during the 2020 Southern hemisphere winter.
Aim To describe trends of RSV related disease in children in the Northern hemisphere and to propose a low cost clinical surveillance system based on primary care electronic health records (EHR).
Methods Time series analysis of RSV-related disease and virus laboratory-confirmations in children under 5 years old from 1 September 2009 to 16 January 2021. We collected RSV diagnoses from primary care EHR in Catalonia (Spain). We compared the trend of RSV in the season 2020-2021 with that in the previous seasons. We estimated the expected RSV cases with data from 2009 to 2018 using a time series regression adjusted by seasonality. We used the same method to estimate the expected RSV laboratory-confirmations as a sensitivity analysis.
Results In previous seasons, RSV-related disease peaks in Catalonia during the weeks 52 and 53. However in the 2020-2021 period, we observed a reduction of 87.6% (95% CI: 82.7% to 90.3%) in RSV-related disease from october 2020 compared to the expected. Only 1 RSV case was laboratory-confirmed during the 2020-2021 season until mid-January.
Conclusions We observed a nearly absence of RSV-related disease and laboratory-confirmations during the weeks when RSV usually peaks in Catalonia. The use of primary care EHR could be a low-cost surveillance system to monitorize trends of RSV the coming months.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AA and JV work was partially supported by national Plan of RDI 2008 to 2011 and by Carlos III Health Institute, Subdirectorate-General of networks and cooperative research Centers, Spanish Ministry of Economy and Competitiveness, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003); By Health Research Fund, Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and PI18/00685); and European Regional Development Fund (ERDF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was done in accordance with existing statutory and ethical approvals from the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/172-PCV) and the Vall Hebron Hospital Campus Clinical Research Ethics Committee (PR(AMI)556/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: None declared.
Funding statement: AA and JV’s work was partially supported by national Plan of R + D + I 2008–2011 and by Carlos III Health Institute, Subdirectorate-General of networks and cooperative research Centers, Spanish Ministry of Economy and Competitiveness, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003); By Health Research Fund, Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and PI18/00685); and European Regional Development Fund (ERDF).
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.